Bausch Health Expands Fraxel FTX Skin Resurfacing Tech to Australia
Event summary
- Bausch Health's Solta Medical launched Fraxel FTX skin resurfacing technology in Australia on September 1, 2026.
- Fraxel FTX features dual wavelengths, precision treatment delivery, and ergonomic design enhancements.
- The technology addresses fine lines, wrinkles, scars, dyschromia, and actinic keratosis.
- Solta Medical provides clinical education and business support to healthcare practitioners in Australia and New Zealand.
The big picture
Bausch Health's expansion of Fraxel FTX into Australia underscores its strategy to strengthen its position in the global aesthetics market. The launch builds on over 20 years of innovation in skin resurfacing, targeting a range of common skin concerns. This move aligns with broader industry trends towards advanced, non-invasive aesthetic solutions, positioning Bausch Health to capitalize on growing demand for skin health treatments.
What we're watching
- Market Penetration
- How quickly Fraxel FTX will gain adoption among Australian healthcare practitioners.
- Competitive Positioning
- Whether Bausch Health can sustain its leadership in the aesthetics market with this technology.
- Regulatory Compliance
- The pace at which regulatory approvals for similar technologies will be granted in other regions.